Value
3.3/10data confidence 100%| Component | Sub-score |
|---|---|
| P/E | 2.4 |
| P/S | 0.5 |
| EV/EBITDA | 0.0 |
| Fwd P/E | 2.9 |
| PEG | 4.4 |
| Analyst target | 7.5 |
- ▸Forward P/E: 36.1x
- ▸PEG: 2.10
ISRG · Why this verdict
Why Intuitive Surgical (ISRG) is rated HOLD
Updated
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
VerdictHOLD
Overall score6.0/10
ConfidenceMEDIUM
MacroNEUTRAL
Thesis pillars
| Pillar | Expectation | Trend |
|---|---|---|
The business scores a perfect 9 out of 9 on the Piotroski financial health scale, carries operating margins of 28%, ranks best-in-class on margins versus peers, and clears the Rule of 40 at a combined score of 44 — collectively reflecting a franchise with durable earnings quality and structural competitive strength. Quality breakdown | Operating margin stays above 25% and Piotroski F-Score remains at 8 or above for four consecutive quarters. | →Stable |
| CounterHigh margins in a medical device business can attract competitive responses or face pricing pressure from hospital procurement consolidation; a sole- and single-sourced supplier concentration flagged in company disclosures could also create a production disruption that temporarily compresses margins within a single quarter. | ||
Revenue is growing at 23% year-over-year and the combined growth-plus-margin score of 44 clears the Rule of 40 threshold, indicating the business is expanding without sacrificing profitability — a combination that typically supports a durable premium multiple. Growth breakdown | Revenue growth rate stays above 18% year-over-year for two consecutive quarters while gross margin remains above 60%. | →Stable |
| CounterThe sole- and single-sourced supplier risk flagged in company disclosures means any supply disruption could create a production shortfall that cuts into the revenue growth rate within a single quarter, and a 23% growth rate from this starting base will naturally decelerate as the installed base matures. | ||
The company has delivered four consecutive earnings beats with an average surprise of roughly 16%, demonstrating a consistent pattern of under-promising and over-delivering relative to analyst consensus. Catalyst breakdown | The beat streak extends to at least five consecutive quarters with each surprise staying above 5%. | →Stable |
| CounterA 16% average beat, while meaningful, is not dramatically above what well-covered large-caps routinely deliver; if Wall Street ratchets estimates upward in response to repeated outperformance, the manageable bar that produced these beats may rise to a level that is materially harder to clear. | ||
At a forward price-to-earnings multiple of 35x and a PEG ratio of 2.18, the stock already prices in substantial optimism; simultaneously, the price is in a confirmed downtrend below a declining 200-day moving average, creating a combination where the rich starting multiple leaves little room for earnings disappointment. Bear case | Forward P/E compresses below 28x while the stock recovers above its 200-day moving average. | →Stable |
| CounterA franchise with near-perfect financial health scores and a consistent beat record can sustain a premium multiple for extended periods; a rich valuation alone is not a sufficient catalyst for sustained drawdown if earnings continue to outperform consensus. | ||
The options market shows a put/call ratio of 5.85 — an unusually high reading indicating that protective put purchasing far exceeds call activity, suggesting participants are collectively positioned for near-term downside risk. Risk breakdown | Put/call ratio normalizes below 2.0 in the 30 days following the next earnings release. | →Stable |
| CounterAn elevated put/call ratio in a widely-held large-cap may reflect institutional holders adding hedges to existing long positions rather than outright directional short bets; if that is the case, the signal overstates bearish conviction and the ratio will normalize naturally as the hedges expire. | ||
The business scores a perfect 9 out of 9 on the Piotroski financial health scale, carries operating margins of 28%, ranks best-in-class on margins versus peers, and clears the Rule of 40 at a combined score of 44 — collectively reflecting a franchise with durable earnings quality and structural competitive strength.
→StableQuality breakdown
- Expectation
- Operating margin stays above 25% and Piotroski F-Score remains at 8 or above for four consecutive quarters.
CounterHigh margins in a medical device business can attract competitive responses or face pricing pressure from hospital procurement consolidation; a sole- and single-sourced supplier concentration flagged in company disclosures could also create a production disruption that temporarily compresses margins within a single quarter.
Revenue is growing at 23% year-over-year and the combined growth-plus-margin score of 44 clears the Rule of 40 threshold, indicating the business is expanding without sacrificing profitability — a combination that typically supports a durable premium multiple.
→StableGrowth breakdown
- Expectation
- Revenue growth rate stays above 18% year-over-year for two consecutive quarters while gross margin remains above 60%.
CounterThe sole- and single-sourced supplier risk flagged in company disclosures means any supply disruption could create a production shortfall that cuts into the revenue growth rate within a single quarter, and a 23% growth rate from this starting base will naturally decelerate as the installed base matures.
The company has delivered four consecutive earnings beats with an average surprise of roughly 16%, demonstrating a consistent pattern of under-promising and over-delivering relative to analyst consensus.
→StableCatalyst breakdown
- Expectation
- The beat streak extends to at least five consecutive quarters with each surprise staying above 5%.
CounterA 16% average beat, while meaningful, is not dramatically above what well-covered large-caps routinely deliver; if Wall Street ratchets estimates upward in response to repeated outperformance, the manageable bar that produced these beats may rise to a level that is materially harder to clear.
At a forward price-to-earnings multiple of 35x and a PEG ratio of 2.18, the stock already prices in substantial optimism; simultaneously, the price is in a confirmed downtrend below a declining 200-day moving average, creating a combination where the rich starting multiple leaves little room for earnings disappointment.
→StableBear case
- Expectation
- Forward P/E compresses below 28x while the stock recovers above its 200-day moving average.
CounterA franchise with near-perfect financial health scores and a consistent beat record can sustain a premium multiple for extended periods; a rich valuation alone is not a sufficient catalyst for sustained drawdown if earnings continue to outperform consensus.
The options market shows a put/call ratio of 5.85 — an unusually high reading indicating that protective put purchasing far exceeds call activity, suggesting participants are collectively positioned for near-term downside risk.
→StableRisk breakdown
- Expectation
- Put/call ratio normalizes below 2.0 in the 30 days following the next earnings release.
CounterAn elevated put/call ratio in a widely-held large-cap may reflect institutional holders adding hedges to existing long positions rather than outright directional short bets; if that is the case, the signal overstates bearish conviction and the ratio will normalize naturally as the hedges expire.
TrendMatrix Research · core thesis
Engine thesis — one sentence
Intuitive Surgical is a high-quality franchise — a perfect Piotroski financial-health score, 28% operating margins ranked best-in-class among peers, and four consecutive earnings beats — but the stock carries a forward multiple of 35x in a confirmed price downtrend with a put/call ratio of 5.85, arguing that the setup rewards waiting for either a better entry price or a technical reversal signal before adding exposure.
Falsifiable statement — pillar-level invalidators below. Engine-derived; not personalized advice.
Per-dimension breakdown
Quality
8.1/10data confidence 100%| Component | Sub-score |
|---|---|
| ROE | 5.7 |
| ROA | 6.8 |
| Gross margin | 9.3 |
| Op margin | 10.0 |
| Net margin | 10.0 |
| Current ratio | 8.4 |
| FCF quality | 5.7 |
| Moat | 7.4 |
| Rule of 40 | 7.5 |
| Piotroski F | 10.0 |
- ▸Strong margins: 28%
- ▸Earnings quality warning: 76% FCF/NI
- ▸Rule of 40: 44 (pass)
- ▸Strong Piotroski F-Score: 9/9
Growth
7.0/10data confidence 67%| Component | Sub-score |
|---|---|
| Rev growth | 8.2 |
| EPS growth | 5.8 |
- ▸Strong growth: 23% YoY
Momentum
6.7/10data confidence 100%| Component | Sub-score |
|---|---|
| RSI | 4.5 |
| MACD | 10.0 |
| OBV | 10.0 |
| MA position | 4.0 |
| Volume | 4.9 |
- ▸Volume accumulation (rising OBV)
- ▸Below 200-MA, MA slope -1.6%/30d — confirmed downtrend
Sentiment
6.2/10data confidence 100%| Component | Sub-score |
|---|---|
| LLM sentiment | 5.2 |
| Analyst rating | 5.0 |
| Price target | 8.8 |
- ▸Analyst upside: 33%
Insider
5.0/10data confidence 50%| Component | Sub-score |
|---|---|
| materiality | 5.0 |
| holder change | 5.1 |
- ▸Negligible insider selling — $3,094,262 (0.002% of mkt cap)
Peer rank
5.9/10data confidence 80%| Component | Sub-score |
|---|---|
| value rank | 1.8 |
| quality rank | 8.9 |
| growth rank | 8.0 |
- ▸Superior ROE vs peers
- ▸Best-in-class margins
Technical
2.8/10data confidence 100%| Component | Sub-score |
|---|---|
| bollinger | 0.7 |
| support resistance | 1.5 |
| 52w position | 4.1 |
| gap | 5.0 |
Risk (lower is worse)
6.1/10data confidence 100%| Component | Sub-score |
|---|---|
| short interest | 8.9 |
| days to cover | 7.6 |
| volatility | 5.5 |
| put call | 5.3 |
| implied vol | 4.0 |
| beta | 5.2 |
- ▸Concentration risks: 1 HIGH, 2 MED (10-K Item 1A — sized via position_sizing, validated via buy_confidence)
Catalyst
7.6/10data confidence 100%| Component | Sub-score |
|---|---|
| erm | 5.0 |
| earnings history | 10.0 |
| earnings timing | 5.0 |
| surprise avg | 10.0 |
| news activity | 8.0 |
- ▸Perfect beat streak: 4Q
- ▸Earnings in 13 days
How the verdict was assembled
Engine trigger
Maintain position. Not compelling to add more.
Engine technical detail
verdict_path:
L4:PATH_F_HOLDPassed (7)
- MOMENTUM:6.7>=5.5
- ASYMMETRY:2.9>=1.5
- INSIDER:OK
- DEATH_CROSS:QUALITY_MOMENTUM_EXEMPT
- NEWS_EVENTS:NONE_RECENT
- SEMI_CYCLE_PEAK:CLEAR
- MATERIALS_CYCLE_PEAK:CLEAR
Failed (0)
none
Warning (3)
- DEATH_CROSS:quality=8.1>=7.5+momentum=6.7>=5.0 exempted
- 8K_CSUITE_CHANGE:5.02 (officer departure/appointment)
- EARNINGS_PROXIMITY:13d<=14d (soft)
Reward-to-Risk
2.90
Upside
+19.4%
Downside
6.7%
Sizing output
AVOID
SetupRecovery — Death cross but MACD improving, RSI 58
EdgeCatalyst-Driven — Earnings in 13d with 4/4 beat streak
SuitabilityAggressive — Beta 1.46>1.3
Investment implication
None of the engine's positive-conviction paths (C-quality, D-momentum) triggered — the F-path HOLD reflects balanced signals. Strongest-cleared gate: MOMENTUM:6.7>=5.5. Top dim: Quality at 8.1; weakest: Technical at 2.8. No conviction either direction.
The strongest dimensions are Quality at 8.1, Catalyst at 7.6, and Growth at 7.0; the weakest are Technical at 2.8, Value at 3.3, and Insider at 5.0. The V9 engine cleared all gates with 3 warnings, producing an asymmetric reward-to-risk of 2.90 and an engine sizing output of AVOID.
What would invalidate the thesis
Falsifying conditions — when triggered, the corresponding pillar's thesis is invalidated.
- P1High Quality Franchise Perfect Health
Trip ifOperating margin compresses below 20% for 2 consecutive quarters.
- P2Consistent Earnings Outperformance
Trip ifEPS surprise falls below 0% for 2 consecutive quarters.
- P3Strong Revenue Growth Rule Of 40
Trip ifRevenue growth falls below 15% YoY for 2 consecutive quarters.
- P4Rich Valuation Confirmed Downtrend
Trip ifPrice crosses above the 200-day moving average and holds above it for at least 10 consecutive trading sessions while forward P/E compresses to below 28x.
- P5Elevated Put Call Defensive Positioning
Trip ifPut/call ratio falls below 2.0 for at least 3 consecutive options-expiration cycles.